Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage chronic conditions such as diabetes and heart disease and others to help them lose weight.

Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

Most patients still need to be managed by oral medications to treat diabetes and not injections, at least in the early stages, says endocrinologist

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 billion proposal from the Biden administration is blessed by President-elect Donald Trump.

The Biden-Harris administration proposed a new rule on Tuesday that would expand coverage of the anti-obesity medications known as GLP-1 treatments for Medicare and Medicaid beneficiaries. Medicare is currently only allowed to cover these medications for weight loss if they are prescribed to treat a second condition as well.

Millions of Americans with obesity would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare and Medicaid under a new rule the Biden administration proposed Tuesday morning.

The Biden administration wants to expand access to popular weight loss drugs like Wegovy and Ozempic. The new proposal would allow millions of obese Americans covered by Medicaid and Medicare to be eligible for the drugs.